{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:38:10Z","timestamp":1764571090037},"reference-count":123,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,12,12]]},"DOI":"10.18632\/oncotarget.28541","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T14:04:59Z","timestamp":1702389899000},"page":"977-994","source":"Crossref","is-referenced-by-count":2,"title":["Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability"],"prefix":"10.18632","volume":"14","author":[{"given":"Fl\u00e1via Dias","family":"Xavier","sequence":"first","affiliation":[{"name":"Hospital Universit\u00e1rio de Bras\u00edlia-Universidade de Bras\u00edlia\/Ebserh, Bras\u00edlia, DF, Brazil"},{"name":"Hospital DF Star, Oncologia D\u2019Or, Rede D\u2019Or, Bras\u00edlia, DF, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle Le\u00e3o Cordeiro de","family":"Farias","sequence":"additional","affiliation":[{"name":"Hospital A Benefic\u00eancia Portuguesa de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrah\u00e3o Elias Hallack","family":"Neto","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glaciano Nogueira","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Hematol\u00f3gica\/Grupo Oncoclinicas, Belo Horizonte, MG, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aurelio Salvino de","family":"Araujo","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia, Salvador, BA, Brazil"},{"name":"Instituto D'Or de Pesquisa e Ensino, IDOR, BA, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Xavier","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Par\u00e1, Bel\u00e9m, PA, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otavio Cesar Carvalho Guimar\u00e3es","family":"Baiocchi","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"},{"name":"Hospital Alem\u00e3o Oswaldo Cruz, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)","author":"Thiele","year":"2017"},{"key":"2","doi-asserted-by":"publisher","first-page":"e987","DOI":"10.1097\/MD.0000000000000987","article-title":"Prevalence of Common Non-Hodgkin Lymphomas and Subtypes of Hodgkin Lymphoma by Nodal Site of Involvement: A Systematic Retrospective Review of 938 Cases","volume":"9","author":"Brousset","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hon.2450","article-title":"Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry","volume":"3","author":"Boquimpani","year":"2018","journal-title":"Hematol Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"39","author":"Friedberg","year":"2021","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"publisher","first-page":"92978","DOI":"10.18632\/oncotarget.21722","article-title":"Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"6","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"2","author":"Greil","year":"2010","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"36","author":"S\u00f6kler","year":"2010","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin\u2019s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)","volume":"2","author":"Hancock","year":"2005","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"3","author":"Friedberg","year":"2013","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin\u2019s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"2","author":"Pettengell","year":"2009","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score \u2265 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial","volume":"3","author":"Aurer","year":"2016","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi","volume":"3","author":"Scalzulli","year":"2016","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","article-title":"ABVD or BEACOPP(baseline) along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d\u2019\u00c9tude des Lymphomes de l\u2019Adulte (GELA) H9-U intergroup randomised trial","volume":"8","author":"van Imhoff","year":"2017","journal-title":"Eur J Cancer"},{"key":"14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"38","author":"Sweetenham","year":"2015","journal-title":"Lancet"},{"key":"15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"2","author":"Kriachok","year":"2021","journal-title":"Lancet Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"3","author":"Lister","year":"2014","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-l","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"34","author":"Hudson","year":"1993","journal-title":"Lancet"},{"key":"18","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"35","author":"Koch","year":"2002","journal-title":"Lancet"},{"key":"19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cncr.21587","article-title":"Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma","volume":"10","author":"Crump","year":"2006","journal-title":"Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma","volume":"1","author":"Burns","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"21","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","article-title":"Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma","volume":"2","author":"Sureda","year":"2010","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"36","author":"Zaja","year":"2011","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2141.2012.09096.x","article-title":"Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL","volume":"15","author":"Ardeshna","year":"2012","journal-title":"Br J Haematol"},{"key":"24","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.21.01552","article-title":"Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress","volume":"3","author":"Bartlett","year":"2021","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"37","author":"Feldman","year":"2018","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1182\/blood-2017-09-772681","article-title":"Management of relapsed\/refractory classical Hodgkin lymphoma in transplant-ineligible patients","volume":"13","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"27","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"13","author":"Steidl","year":"2018","journal-title":"Blood"},{"key":"28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1186\/s12885-020-07561-2","article-title":"Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: a European expert perspective","volume":"2","author":"Walewski","year":"2020","journal-title":"BMC Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1182\/blood.2020007900","article-title":"How I incorporate novel agents into the treatment of classical Hodgkin lymphoma","volume":"13","author":"Herrera","year":"2021","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-020-00603-3","article-title":"Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?","volume":"1","author":"Mei","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"31","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.3390\/cancers13153745","article-title":"Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma","volume":"1","author":"Andr\u00e9","year":"2021","journal-title":"Cancers (Basel)"},{"key":"32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"7","author":"Jemal","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"7","author":"Bray","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"34","unstructured":"Brasil. Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Estimativa 2020 : incid\u00eancia de c\u00e2ncer no Brasil. Rio de Janeiro: INCA, 2019. Available at https:\/\/www.inca.gov.br\/sites\/ufu.sti.inca.local\/files\/media\/document\/estimativa-2020-incidencia-de-cancer-no-brasil.pdf (Accessed 25 January 2022)."},{"key":"35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ijc.31096","article-title":"Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry","volume":"14","author":"Boquimpani","year":"2018","journal-title":"Int J Cancer"},{"key":"36","first-page":"439","article-title":"Intensified ABVP chemotherapy for the primary treatment of Hodgkin\u2019s disease","volume":"9","author":"Pulcheri","year":"2002","journal-title":"Oncol Rep"},{"key":"37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1748-717X-1-38","article-title":"Chemotherapy followed by low dose radiotherapy in childhood Hodgkin\u2019s disease: retrospective analysis of results and prognostic factors","volume":"1","author":"Salvajoli","year":"2006","journal-title":"Radiat Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pbc.20883","article-title":"Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil","volume":"4","author":"Howard","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"39","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/1097-0142(19930501)71:9%3c2823::aid-cncr2820710923%3e3.0.co;2-6","article-title":"C-MOPP\/ABV yields good results in a public hospital population with Hodgkin disease in Brazil","volume":"7","author":"Brabo","year":"1993","journal-title":"Cancer"},{"key":"40","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3109\/10428194.2015.1094696","article-title":"Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma","volume":"5","author":"Yahalom","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"41","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"2","author":"Ladetto","year":"2018","journal-title":"Ann Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"102048","DOI":"10.1016\/j.canep.2021.102048","article-title":"Ethnic, racial and socioeconomic disparities in breast cancer survival in two Brazilian capitals between 1996 and 2012","volume":"7","author":"de Azevedo E Silva","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"43","doi-asserted-by":"publisher","first-page":"101660","DOI":"10.1016\/j.canep.2019.101660","article-title":"Association of cervical and breast cancer mortality with socioeconomic indicators and availability of health services","volume":"6","author":"Souza","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3322\/caac.21586","article-title":"Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy","volume":"7","author":"Wender","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1055-9965.EPI-15-0756","article-title":"Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study","volume":"2","author":"Glaser","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"46","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"12","author":"Yahalom","year":"2015","journal-title":"Cancer"},{"key":"47","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/ijc.22417","article-title":"Socioeconomic inequality and short-term outcome in Hodgkin\u2019s lymphoma","volume":"12","author":"Spector","year":"2007","journal-title":"Int J Cancer"},{"key":"48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/cncr.32584","article-title":"Association between facility volume and mortality of patients with classic Hodgkin lymphoma","volume":"12","author":"Ansell","year":"2020","journal-title":"Cancer"},{"key":"49","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"1","author":"Ansell","year":"2013","journal-title":"Lancet Oncol"},{"key":"50","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Ramchandren","year":"2021","journal-title":"Lancet Haematol"},{"key":"51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"38","author":"Savage","year":"2022","journal-title":"N Engl J Med"},{"key":"52","unstructured":"National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Hodgkin Lymphoma - v.1.2022. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/hogkins.pdf (Accessed on 10 January 2022)."},{"key":"53","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Zimmermann","year":"2020","journal-title":"JAMA Oncol"},{"key":"54","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"3","author":"Ouyang","year":"2019","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"13","author":"Chmiel","year":"2021","journal-title":"Blood"},{"key":"56","first-page":"1258","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin\u2019s disease","volume":"2","author":"Frei","year":"1967","journal-title":"Cancer Res"},{"key":"57","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"3","author":"Connors","year":"2012","journal-title":"J Clin Oncol"},{"key":"58","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"12","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"59","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"12","author":"Younes","year":"2016","journal-title":"Blood"},{"key":"60","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","article-title":"Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation","volume":"12","author":"Zain","year":"2012","journal-title":"Blood"},{"key":"61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Forero-Torres","year":"2014","journal-title":"J Hematol Oncol"},{"key":"62","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"13","author":"McClendon","year":"2018","journal-title":"Blood"},{"key":"63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi","volume":"9","author":"Fondazione Italiana Linfomi","year":"2019","journal-title":"Blood Cancer J"},{"key":"64","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"1","author":"Schwartz","year":"2018","journal-title":"Lancet Oncol"},{"key":"65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"13","author":"Vose","year":"2018","journal-title":"Blood"},{"key":"66","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Coye","year":"2021","journal-title":"Lancet Haematol"},{"key":"67","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"10","author":"Tonino","year":"2021","journal-title":"Haematologica"},{"key":"68","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"3","author":"Moreno","year":"2019","journal-title":"Ann Oncol"},{"key":"69","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"18","author":"Vose","year":"2020","journal-title":"Br J Haematol"},{"key":"70","doi-asserted-by":"publisher","first-page":"7530","DOI":"10.1200\/JCO.2021.39.15_suppl.7530","article-title":"Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?","volume":"3","author":"Kharfan-Dabaja","year":"2021","journal-title":"J Clin Oncol"},{"key":"71","doi-asserted-by":"publisher","first-page":"796270","DOI":"10.3389\/fonc.2021.796270","article-title":"Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review","volume":"1","author":"Das","year":"2021","journal-title":"Front Oncol"},{"key":"72","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"3","author":"Moskowitz","year":"2016","journal-title":"J Clin Oncol"},{"key":"73","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"3","author":"Shipp","year":"2017","journal-title":"J Clin Oncol"},{"key":"74","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"37","author":"Ligon","year":"2015","journal-title":"N Engl J Med"},{"key":"75","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"3","author":"Savage","year":"2018","journal-title":"J Clin Oncol"},{"key":"76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"13","author":"Ng","year":"2019","journal-title":"Blood"},{"key":"77","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"1","author":"Savage","year":"2016","journal-title":"Lancet Oncol"},{"key":"78","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"12","author":"Lazarovici","year":"2017","journal-title":"Blood"},{"key":"79","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"13","author":"Taft","year":"2021","journal-title":"Blood"},{"key":"80","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1080\/10428194.2021.1957865","article-title":"Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"6","author":"von Tresckow","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"81","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.critrevonc.2015.03.011","article-title":"Experience of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma and relapsed\/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature","volume":"9","author":"Bonthapally","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"82","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.critrevonc.2016.04.019","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma: An updated review of published data from the named patient program","volume":"10","author":"Bonthapally","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"83","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1634\/theoncologist.2016-0112","article-title":"Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients","volume":"2","author":"Zinzani","year":"2016","journal-title":"Oncologist"},{"key":"84","doi-asserted-by":"publisher","first-page":"91703","DOI":"10.18632\/oncotarget.18114","article-title":"Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed\/refractory Hodgkin\u2019s lymphoma","volume":"8","author":"Santoro","year":"2017","journal-title":"Oncotarget"},{"key":"85","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.7150\/jca.29308","article-title":"Treatment of Relapsed\/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia","volume":"1","author":"Du\u0161ek","year":"2019","journal-title":"J Cancer"},{"key":"86","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/ejh.12973","article-title":"Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study","volume":"9","author":"Illidge","year":"2017","journal-title":"Eur J Haematol"},{"key":"87","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1080\/10428194.2017.1421762","article-title":"Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries","volume":"5","author":"Zaja","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"88","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/s00277-018-3379-5","article-title":"Brentuximab vedotin as salvage treatment in Hodgkin lymphoma na\u00efve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP)","volume":"9","author":"Scalzulli","year":"2018","journal-title":"Ann Hematol"},{"key":"89","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"9","author":"Radford","year":"2013","journal-title":"Haematologica"},{"key":"90","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bjh.14898","article-title":"Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting","volume":"17","author":"Booth","year":"2017","journal-title":"Br J Haematol"},{"key":"91","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"13","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"92","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bjh.15539","article-title":"Prospective study of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy","volume":"18","author":"Huebner","year":"2018","journal-title":"Br J Haematol"},{"key":"93","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/hon.2897","article-title":"Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study","volume":"3","author":"Gunes","year":"2021","journal-title":"Hematol Oncol"},{"key":"94","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2939","article-title":"Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience","volume":"4","author":"Gini","year":"2022","journal-title":"Hematol Oncol"},{"key":"95","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/10428194.2017.1382698","article-title":"Real-world effectiveness of brentuximab vedotin versus physicians\u2019 choice chemotherapy in patients with relapsed\/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany","volume":"5","author":"Illidge","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"96","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"2","author":"Kaynar","year":"2017","journal-title":"Ann Oncol"},{"key":"97","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s00277-020-04077-4","article-title":"Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience","volume":"9","author":"Kaynar","year":"2020","journal-title":"Ann Hematol"},{"key":"98","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","article-title":"Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide","volume":"2","author":"Gladstone","year":"2018","journal-title":"Blood Adv"},{"key":"99","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.bbmt.2020.02.003","article-title":"Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse\/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain","volume":"2","author":"Barrenetxea","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"100","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis","volume":"2","author":"Giri","year":"2019","journal-title":"Oncologist"},{"key":"101","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1182\/blood-2021-153200","article-title":"Outcomes of Anti-PD1 Treatment for Relapsed\/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis","volume":"13","author":"Kr\u00fcger","year":"2021","journal-title":"Blood"},{"key":"102","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hon.2604","article-title":"Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma","volume":"3","author":"Buccheri","year":"2019","journal-title":"Hematol Oncol"},{"key":"103","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/hon.2796","article-title":"Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem-cell transplantation: Real-life experience","volume":"3","author":"Rocha","year":"2021","journal-title":"Hematol Oncol"},{"key":"104","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1590\/1806-9282.62.suppl1.34","article-title":"Hodgkin\u2019s Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cant\u00eddio - Fortaleza, Brazil","volume":"6","author":"Pitombeira","year":"2016","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"105","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5581\/1516-8484.20110007","article-title":"Autologous hematopoietic stem cell transplantation in classical Hodgkin\u2019s lymphoma","volume":"3","author":"Chamone Dde","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"106","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3816\/CLM.2009.n.088","article-title":"Brazilian experience using high-dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"9","author":"De Souza","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"107","first-page":"522","article-title":"High-dose therapy with autologous transplantation for Hodgkin\u2019s disease: the Bologna experience","volume":"8","author":"Stefoni","year":"2003","journal-title":"Haematologica"},{"key":"108","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/hon.2014","article-title":"High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors","volume":"3","author":"Martinelli","year":"2013","journal-title":"Hematol Oncol"},{"key":"109","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbmt.2017.01.079","article-title":"Human Leukocyte Antigen-Haploidentical Transplantation for Relapsed\/Refractory Hodgkin Lymphoma: A Multicenter Analysis","volume":"2","author":"Rocha","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"110","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1590\/s0034-89102010000400005","article-title":"Rational use of anticancer drugs and patient lawsuits in the state of S\u00e3o Paulo, Southeastern Brazil","volume":"4","author":"Osorio-de-Castro","year":"2010","journal-title":"Rev Saude Publica"},{"key":"111","unstructured":"Brasil. Instituto Brasileiro de Geografia e Estat\u00edstica. Pesquisa Nacional de Sa\u00fade, 2019. Informa\u00e7\u00f5es sobre domic\u00edlios, acesso e utiliza\u00e7\u00e3o dos servi\u00e7os de sa\u00fade. Available at https:\/\/biblioteca.ibge.gov.br\/visualizacao\/livros\/liv101748.pdf (Accessed 29 January 2022)."},{"key":"112","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3389\/fphar.2020.01128","article-title":"Strategies Implemented by Public Institutions to Approach the Judicialization of Health Care in Brazil: A Systematic Scoping Review","volume":"1","author":"Lopes","year":"2020","journal-title":"Front Pharmacol"},{"key":"113","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas Linfoma de Hodgkin no Adulto. Available at http:\/\/conitec.gov.br\/images\/Protocolos\/20201230_PCDT_Linfoma-de-Hodgkin.pdf (Accessed 28 January 2022)."},{"key":"114","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: improving the therapeutic index","volume":"12","author":"Kelly","year":"2015","journal-title":"Blood"},{"key":"115","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","article-title":"Balancing risk and benefit in early-stage classical Hodgkin lymphoma","volume":"13","author":"Engert","year":"2018","journal-title":"Blood"},{"key":"116","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"18","author":"Illidge","year":"2019","journal-title":"Br J Haematol"},{"key":"117","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1080\/10428194.2020.1783443","article-title":"Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment","volume":"6","author":"Matasar","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"118","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1080\/10428194.2018.1540781","article-title":"Survivors\u2019 perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group","volume":"6","author":"Borchmann","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"119","unstructured":"Adcetris (brentuximab vedotin). Highlights of Prescribing Information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125388_s056s078lbl.pdf (Accessed 27 Jan 2022)."},{"key":"120","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy","volume":"3","author":"Beaven","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"121","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/bjh.14316","article-title":"Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma","volume":"17","author":"Thomas","year":"2016","journal-title":"Br J Haematol"},{"key":"122","unstructured":"Opdivo (nivolumab). Highlights of Prescribing Information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125554s091lbl.pdf (Accessed 27 Jan 2022)."},{"key":"123","unstructured":"Keytruda (pembrolizumab). Highlights of Prescribing Information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf (Accessed 27 Jan 2022)."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T14:05:28Z","timestamp":1702389928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":123,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,12]]}},"alternative-id":["28541"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28541","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}